Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM. Fiscus SA, et al. Among authors: lathey jl. J Infect Dis. 1998 Mar;177(3):625-33. doi: 10.1086/514248. J Infect Dis. 1998. PMID: 9498441 Clinical Trial.
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.
Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA. Lathey JL, et al. J Infect Dis. 1998 Mar;177(3):617-24. doi: 10.1086/514250. J Infect Dis. 1998. PMID: 9498440 Clinical Trial.
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
Lathey JL, Tierney C, Chang SY, D'Aquila RT, Bettendorf DM, Alexander HC, Santini CD, Hughes AM, Barroga CF, Spector SA, Landes JE, Hammer SM, Katzenstein DA. Lathey JL, et al. J Infect Dis. 2001 Dec 1;184(11):1402-11. doi: 10.1086/324427. Epub 2001 Nov 13. J Infect Dis. 2001. PMID: 11709782 Clinical Trial.
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, McNamara J, Hodge J, Hughes MD, Lindsey JC; Pediatric AIDS Clinical Trial Group 381 Study Team. Flynn PM, et al. J Infect Dis. 2004 Jul 15;190(2):271-9. doi: 10.1086/421521. Epub 2004 Jun 18. J Infect Dis. 2004. PMID: 15216461 Clinical Trial.
Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Plasma Viremia Group Laboratories of the AIDS Clinical Trials Group (National Institute of Allergy and Infectious Diseases).
Lathey JL, Fiscus SA, Rasheed S, Kappes JC, Griffith BP, Elbeik T, Spector SA, Reichelderfer PS. Lathey JL, et al. J Clin Microbiol. 1994 Dec;32(12):3064-7. doi: 10.1128/jcm.32.12.3064-3067.1994. J Clin Microbiol. 1994. PMID: 7883903 Free PMC article.
40 results